Conjugates comprising self-immolative groups and methods related thereto
US11413353B2 · kind B2 · utility
6Cited by
14References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 23, 2016 |
| Grant date | Aug 16, 2022 |
| Priority date | — |
| Expiry date | Nov 11, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.